Literature DB >> 19480932

del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia.

C Cameron Yin1, Lynne V Abruzzo, Xiaoyan Qiu, Effrosyni Apostolidou, Jorge E Cortes, L Jeffrey Medeiros, Gary Lu.   

Abstract

The del(15q) chromosomal abnormality is known to occur in acute leukemias, but has rarely been described in chronic myelogenous leukemia (CML). Described here are five cases of CML associated with del(15q): four men and one woman. Bone marrow aspirate smears showed increased blasts in all cases at the time of del(15q) detection, in accelerated phase in two cases and myeloid blast phase in three. Conventional cytogenetic analysis showed t(9;22) and del(15q), as well as other inconsistent clonal abnormalities. All patients received imatinib mesylate; four received additional chemotherapy, and two had allogeneic stem cell transplantation (ASCT). Of the three patients who did not receive ASCT, one died, one was in persistent blast phase, and one was in clinical remission with molecular evidence of residual disease at 16, 6, and 34 months, respectively, after identification of the del(15q). Of the two patients who had ASCT, one died and one was in clinical remission with molecular evidence of disease at 15 and 64 months, respectively, after identification of the del(15q). These findings indicate that del(15q) is a recurrent cytogenetic abnormality that may be seen at initial presentation of advanced disease or may emerge during disease progression. Del(15q) appears to be associated with a poor prognosis in CML.

Entities:  

Mesh:

Year:  2009        PMID: 19480932      PMCID: PMC4167428          DOI: 10.1016/j.cancergencyto.2009.02.017

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  33 in total

Review 1.  The molecular biology of chronic myeloid leukemia.

Authors:  M W Deininger; J M Goldman; J V Melo
Journal:  Blood       Date:  2000-11-15       Impact factor: 22.113

2.  TaqMan RT-PCR assay coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type.

Authors:  Rajyalakshmi Luthra; Beatriz Sanchez-Vega; L Jeffrey Medeiros
Journal:  Mod Pathol       Date:  2004-01       Impact factor: 7.842

3.  Deletion of chromosome arm 15q and hitherto unreported duplication of del(15q) in myeloid disorders.

Authors:  K Saunders; Y Williams; M Aldouri; N Telford; B Czepulkowski
Journal:  Cancer Genet Cytogenet       Date:  2004-06

4.  Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.

Authors:  S Sacchi; H M Kantarjian; S O'Brien; J Cortes; M B Rios; F J Giles; M Beran; C A Koller; M J Keating; M Talpaz
Journal:  Cancer       Date:  1999-12-15       Impact factor: 6.860

5.  A distinct tumor suppressor gene locus on chromosome 15q21.1 in sporadic form of colorectal cancer.

Authors:  W S Park; J Y Park; R R Oh; N J Yoo; S H Lee; M S Shin; H K Lee; S Han; S K Yoon; S Y Kim; C Choi; P J Kim; S T Oh; J Y Lee
Journal:  Cancer Res       Date:  2000-01-01       Impact factor: 12.701

6.  A unique, complex variant philadelphia chromosome translocation in a patient with typical chronic myelogenous leukemia.

Authors:  R Oudat; Z Khan; A B Glassman
Journal:  Arch Pathol Lab Med       Date:  2001-03       Impact factor: 5.534

7.  Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.

Authors:  J D Rowley
Journal:  Nature       Date:  1973-06-01       Impact factor: 49.962

8.  t(8;21)(q22;q22) in blast phase of chronic myelogenous leukemia.

Authors:  C Cameron Yin; L Jeffrey Medeiros; Armand B Glassman; Pei Lin
Journal:  Am J Clin Pathol       Date:  2004-06       Impact factor: 2.493

Review 9.  Clonal evolution in chronic myelogenous leukemia.

Authors:  Jorge Cortes; Michael E O'Dwyer
Journal:  Hematol Oncol Clin North Am       Date:  2004-06       Impact factor: 3.722

Review 10.  Deletion 15q as the sole abnormality in acute myeloid leukemia: report of three cases and review of the literature.

Authors:  Gary Lu; C Cameron Yin; L Jeffrey Medeiros; Lynne V Abruzzo
Journal:  Cancer Genet Cytogenet       Date:  2009-01-15
View more
  3 in total

1.  Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.

Authors:  Preetesh Jain; Hagop M Kantarjian; Ahmad Ghorab; Koji Sasaki; Elias J Jabbour; Graciela Nogueras Gonzalez; Rashmi Kanagal-Shamanna; Ghayas C Issa; Guillermo Garcia-Manero; Devendra Kc; Sara Dellasala; Sherry Pierce; Marina Konopleva; William G Wierda; Srdan Verstovsek; Naval G Daver; Tapan M Kadia; Gautam Borthakur; Susan O'Brien; Zeev Estrov; Farhad Ravandi; Jorge E Cortes
Journal:  Cancer       Date:  2017-07-25       Impact factor: 6.860

2.  The -137G/C Polymorphism in Interleukin-18 Gene Promoter Contributes to Chronic Lymphocytic and Chronic Myelogenous Leukemia Risk in Turkish Patients.

Authors:  Serap Yalçın; Pelin Mutlu; Türker Çetin; Meral Sarper; Gökhan Özgür; Ferit Avcu
Journal:  Turk J Haematol       Date:  2014-05-21       Impact factor: 1.831

3.  Differential prognostic impact of stratified additional chromosome abnormalities on disease progression among Malaysian chronic myeloid leukemia patients undergoing treatment with imatinib mesylate.

Authors:  Ismail Siti Mariam; Ramli Norhidayah; Abu Bakar Zulaikha; Mohd Yunus Nazihah; Hassan Rosline; Ghazali Anis Kausar; Sulong Sarina; Husin Azlan; Ravindran Ankathil
Journal:  Front Oncol       Date:  2022-08-08       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.